DEA Judge Sets Post-Hearing Timeline for Cannabis Rescheduling Decision
Federal rescheduling hearing concludes with judge outlining brief submission deadlines before issuing recommendation on moving cannabis from Schedule I.
The DEA's administrative law judge has established the procedural timeline for the final phase of federal cannabis rescheduling deliberations, following the conclusion of multi-day hearings that began in late 2024. Participating parties now face specific deadlines to submit post-hearing briefs before the judge issues his recommendation on whether to move cannabis from Schedule I to Schedule III under the Controlled Substances Act.
The hearing's completion marks a procedural milestone in what has become the most significant federal cannabis policy review in decades. The rescheduling proposal, which originated during the Biden administration and carries forward under Trump, would maintain cannabis prohibition while reducing regulatory barriers for research and potentially creating new banking and tax advantages for state-licensed operators.
Cannabis operators trading on major exchanges stand to benefit substantially from rescheduling through Section 280E tax relief, which currently prevents businesses from deducting standard operating expenses. Multi-state operators like Curaleaf (OTCQX: CURLF), Green Thumb Industries (OTCQX: GTBIF), and Trulieve (OTCQX: TCNNF) have collectively paid hundreds of millions in additional taxes due to 280E restrictions, directly impacting their profitability and cash flow.
The administrative process creates uncertainty around implementation timelines, even if the judge recommends rescheduling. The final decision rests with the DEA administrator, and any policy change would trigger a complex regulatory framework adjustment across multiple federal agencies. Banking regulations, FDA oversight, and interstate commerce rules would all require coordination between agencies that have historically maintained restrictive cannabis policies.
Market participants continue monitoring the proceedings while state-level programs expand regardless of federal action. The rescheduling debate occurs as cannabis companies face margin pressure from oversupply in mature markets like California and Colorado, making federal tax relief increasingly critical for operator profitability. The judge's upcoming recommendation timeline will provide clarity on when the industry might expect resolution to this multi-year regulatory review process.